X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,273.21% | 2,925.73% | 5,721.31% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,273.21% | 2,925.73% | 5,721.31% | -- | -- |
| Cost of Revenue | 622.33% | 1,050.51% | 1,978.73% | -- | -- |
| Gross Profit | 1,567.95% | 4,403.82% | 9,121.36% | -- | -- |
| SG&A Expenses | -34.79% | -14.96% | 13.49% | 29.33% | 73.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.52% | -3.05% | 11.68% | 25.46% | 33.89% |
| Operating Income | 41.88% | 28.18% | 14.33% | 1.69% | -31.51% |
| Income Before Tax | -113.13% | -468.53% | -673.29% | 111.58% | 63.26% |
| Income Tax Expenses | -86.77% | 251.76% | 258.33% | 249.46% | 297.44% |
| Earnings from Continuing Operations | -111.48% | -467.43% | -678.36% | 111.32% | 62.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.48% | -467.43% | -678.36% | 111.32% | 62.98% |
| EBIT | 41.88% | 28.18% | 14.33% | 1.69% | -31.51% |
| EBITDA | 42.46% | 28.88% | 15.15% | 2.44% | -31.28% |
| EPS Basic | 21.69% | -294.26% | -671.05% | 110.85% | 69.37% |
| Normalized Basic EPS | 80.12% | 46.02% | -12.50% | 35.87% | -17.38% |
| EPS Diluted | 22.06% | -288.01% | -680.37% | 110.72% | 69.23% |
| Normalized Diluted EPS | 80.12% | 46.01% | -12.53% | 35.89% | -17.36% |
| Average Basic Shares Outstanding | 526.99% | 141.07% | 4.42% | 5.88% | 13.20% |
| Average Diluted Shares Outstanding | 526.82% | 141.07% | 4.48% | 6.04% | 13.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |